Frontier Capital Management’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-481,349
| Closed | -$6.22M | – | 311 |
|
|
2025
Q3 | $6.22M | Sell |
481,349
-224,189
| -32% | -$3M | 0.06% | 267 |
|
|
2025
Q2 | $12.6M | Buy |
705,538
+79,640
| +13% | +$1.39M | 0.12% | 226 |
|
|
2025
Q1 | $11.2M | Sell |
625,898
-100,426
| -14% | -$2.28M | 0.12% | 206 |
|
|
2024
Q4 | $21.6M | Sell |
726,324
-145,096
| -17% | -$3.07M | 0.21% | 169 |
|
|
2024
Q3 | $13.6M | Sell |
871,420
-156,911
| -15% | -$2.85M | 0.13% | 199 |
|
|
2024
Q2 | $17.6M | Buy |
1,028,331
+107,215
| +12% | +$1.89M | 0.17% | 183 |
|
|
2024
Q1 | $14.4M | Buy |
921,116
+127,642
| +16% | +$1.88M | 0.13% | 194 |
|
|
2023
Q4 | $11.8M | Buy |
793,474
+369,037
| +87% | +$4.94M | 0.12% | 191 |
|
|
2023
Q3 | $6.85M | Buy |
424,437
+227,942
| +116% | +$6.57M | 0.08% | 215 |
|
|
2023
Q2 | $8.15M | Sell |
196,495
-124,476
| -39% | -$7.73M | 0.08% | 212 |
|
|
2023
Q1 | $19.3M | Sell |
320,971
-21,239
| -6% | -$1.7M | 0.2% | 155 |
|
|
2022
Q4 | $25.1M | Sell |
342,210
-8,061
| -2% | -$607K | 0.27% | 139 |
|
|
2022
Q3 | $26.6M | Sell |
350,271
-4,943
| -1% | -$386K | 0.31% | 117 |
|
|
2022
Q2 | $24.7M | Sell |
355,214
-149,140
| -30% | -$11.2M | 0.28% | 129 |
|
|
2022
Q1 | $41.8M | Buy |
504,354
+71,070
| +16% | +$5.24M | 0.38% | 94 |
|
|
2021
Q4 | $32.5M | Buy |
433,284
+206,517
| +91% | +$20.7M | 0.26% | 131 |
|
|
2021
Q3 | $26.3M | Sell |
226,767
-132,499
| -37% | -$20M | 0.21% | 153 |
|
|
2021
Q2 | $79.7M | Buy |
359,266
+356,364
| +12,280% | +$69.3M | 0.58% | 53 |
|
|
2021
Q1 | $384K | Buy |
+2,902
| New | +$459K | ﹤0.01% | 273 |
|
|
2020
Q4 | – | Sell |
-150,350
| Closed | -$16.7M | – | 291 |
|
|
2020
Q3 | $16.7M | Buy |
150,350
+129,123
| +608% | +$10.3M | 0.15% | 175 |
|
|
2020
Q2 | $1.26M | Sell |
21,227
-150,031
| -88% | -$9.87M | 0.01% | 285 |
|
|
2020
Q1 | $11.5M | Buy |
171,258
+132,202
| +338% | +$10.4M | 0.13% | 181 |
|
|
2019
Q4 | $3.29M | Sell |
39,056
-11,939
| -23% | -$964K | 0.02% | 262 |
|
|
2019
Q3 | $3.81M | Sell |
50,995
-355,838
| -87% | -$28.5M | 0.03% | 256 |
|
|
2019
Q2 | $25.7M | Buy |
406,833
+40,823
| +11% | +$2.07M | 0.19% | 158 |
|
|
2019
Q1 | $17.6M | Buy |
366,010
+20,284
| +6% | +$976K | 0.13% | 200 |
|
|
2018
Q4 | $11.6M | Buy |
345,726
+243,903
| +240% | +$8.92M | 0.09% | 222 |
|
|
2018
Q3 | $5.34M | Sell |
101,823
-254,144
| -71% | -$10.1M | 0.03% | 266 |
|
|
2018
Q2 | $11.1M | Sell |
355,967
-751,932
| -68% | -$20.9M | 0.08% | 233 |
|
|
2018
Q1 | $24.2M | Buy |
1,107,899
+26,001
| +2% | +$559K | 0.18% | 178 |
|
|
2017
Q4 | $21.9M | Buy |
1,081,898
+248,322
| +30% | +$4.78M | 0.16% | 186 |
|
|
2017
Q3 | $16.5M | Buy |
833,576
+6,522
| +0.8% | +$128K | 0.12% | 205 |
|
|
2017
Q2 | $14.3M | Buy |
+827,054
| New | +$10.7M | 0.1% | 220 |
|
Other funds holding NVCR
SCM
QCM
PAI
Frontier Capital Management's NVCR Position: Q4 2025 in Review
Frontier Capital Management sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 481,349 shares — an estimated $6.22M sold.
Frontier Capital Management first reported a position in NVCR in Q2 2017 and held it in 33 quarters. The position peaked at $79.7M in Q2 2021. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.
- Frontier Capital Management reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
- Frontier Capital Management sold 481,349 NovoCure shares in Q4 2025, an estimated $6.22M.
- Frontier Capital Management first reported a position in NovoCure in Q2 2017 and held it in 33 quarters.
- Frontier Capital Management's NovoCure position peaked at $79.7M in Q2 2021.
- 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.
Based on Frontier Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.